RYTM
Rhythm Pharmaceuticals, Inc.
There isn't enough reported data to score RYTM yet.
RYTM Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
RYTM's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
RYTM PE Valuation
RYTM has no meaningful PE right now: it lost money over the past year.
RYTM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect RYTM's losses to grow, with revenue growing. However, they disagree widely on these estimates.
RYTM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.90 | +$0.19 |
| Q2 2026 | -$3.11 | -$0.11 |
| Q1 2026 | -$3.13 | -$0.33 |
| Q4 2025 | -$3.11 | +$1.23 |
| Q3 2025 | -$3.09 | +$1.24 |
| Q2 2025 | -$3.00 | +$1.36 |
| Q1 2025 | -$2.80 | +$1.83 |
| Q4 2024 | -$4.34 | -$1.14 |
RYTM is still losing money, but less than at its worst: $2.90 per share over the past year, against $4.63 at its worst in early 2024.
RYTM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $92.1M | +80% |
| Q2 2026 | $71.3M | +47% |
| Q1 2026 | $60.1M | +84% |
| Q4 2025 | $57.3M | +37% |
| Q3 2025 | $51.3M | +54% |
| Q2 2025 | $48.5M | +67% |
| Q1 2025 | $32.7M | +26% |
| Q4 2024 | $41.8M | +73% |
RYTM's revenue has grown year over year every quarter since early 2022: $92M last quarter, up 80% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -43% | +60 points |
| Q2 2026 | -68% | +25 points |
| Q1 2026 | -87% | +57 points |
| Q4 2025 | -82% | +16 points |
| Q3 2025 | -103% | +29 points |
| Q2 2025 | -93% | +46 points |
| Q1 2025 | -144% | +395 points |
| Q4 2024 | -99% | +72 points |
RYTM's operating margin was −43% last quarter, up 60 points from the same quarter a year ago, near the top of its range since 2021.
RYTM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$9.2M | +$14.2M |
| Q1 2026 | -$44.2M | -$3.8M |
| Q4 2023 | -$29.4M | +$4.6M |
| Q3 2023 | -$29.3M | +$17.8M |
| Q2 2023 | -$41.1M | -$2.2M |
| Q1 2023 | -$36.5M | +$17.3M |
| Q4 2022 | -$34M | +$6.5M |
| Q3 2022 | -$47.1M | -$6.8M |
RYTM has burned cash in almost every quarter: −$103M over the past year, against −$140M the year before.
RYTM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +453K shares |
| 1 year | +4.2% | +2.8M shares |
| 3 years | +19% | +11.2M shares |
| 5 years | +37% | +18.8M shares |
| Available history | +90% | +32.6M shares |
RYTM has 69M diluted shares, up 4.2% from a year ago.
RYTM Net Leverage
RYTM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RYTM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.9 | Neutral |
| Stochastic | 58.5 | Neutral |
RYTM's weekly RSI is 58 (neutral) and its Stochastic is 58 (neutral).
RYTM PE vs Healthcare Sector
RYTM has no meaningful PE right now: it lost money over the past year.
RYTM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $96.6 | 14% above |
| 20 week MA | $102.8 | 6.8% above |
| 50 week MA | $98.3 | 12% above |
| 100 week MA | $87.0 | 26% above |
| 200 week MA | $61.1 | 80% above |
RYTM is in an uptrend: it's above all five of its weekly moving averages, and 80% above its 200-week average.
RYTM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.0 | $29.0 | +26% |
| 2021 | $29.0 | $12.2 | -58% |
| 2022 | $12.2 | $29.2 | +139% |
| 2023 | $29.2 | $46.0 | +57% |
| 2024 | $46.0 | $55.6 | +21% |
| 2025 | $55.6 | $110.0 | +98% |
| 2026 YTD | $110.0 | $109.9 | -0.1% |
RYTM's yearly returns have swung widely, from +139% in 2022 to −58% in 2021. It's roughly flat so far in 2026.